{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T18:08:50Z","timestamp":1783534130330,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ejca.2021.02.007","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T11:09:07Z","timestamp":1616065747000},"page":"95-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy"],"prefix":"10.1016","volume":"148","author":[{"given":"Rachel","family":"Michaelson-Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shira","family":"Gabizon\u2013Peretz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0216-9948","authenticated-orcid":false,"given":"Shunit","family":"Armon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naama","family":"Srebnik-Moshe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pnina","family":"Mor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1756-5801","authenticated-orcid":false,"given":"Ariela","family":"Tomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ephrat","family":"Levy-Lahad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shani","family":"Paluch-Shimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2021.02.007_bib1","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-genom-083118-015253","article-title":"Population screening for inherited predisposition to breast and ovarian cancer","volume":"21","author":"Manchanda","year":"2020","journal-title":"Annu Rev Genom Hum Genet"},{"key":"10.1016\/j.ejca.2021.02.007_bib2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1146\/annurev-biochem-013118-111058","article-title":"The BRCA tumor suppressor network in chromosome damage repair by homologous recombination","volume":"88","author":"Zhao","year":"2019","journal-title":"Annu Rev Biochem"},{"issue":"4","key":"10.1016\/j.ejca.2021.02.007_bib3","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nm.4292","article-title":"HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures","volume":"23","author":"Davies","year":"2017","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.ejca.2021.02.007_bib4","first-page":"1059","article-title":"Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families","volume":"60","author":"Levy-Lahad","year":"1997","journal-title":"Am J Hum Genet"},{"issue":"4","key":"10.1016\/j.ejca.2021.02.007_bib5","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/nm0596-534","article-title":"Ashkenazi Jewish population frequencies for common mutations in BRCA 1 and BRCA2","volume":"2","author":"Giordano","year":"1996","journal-title":"Nat Med"},{"issue":"23","key":"10.1016\/j.ejca.2021.02.007_bib6","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA, J Am Med Assoc"},{"issue":"1","key":"10.1016\/j.ejca.2021.02.007_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/sj.bjc.6603535","article-title":"Cancer risks among BRCA1 and BRCA2 mutation carriers","volume":"96","author":"Levy-Lahad","year":"2007","journal-title":"Br J Canc"},{"issue":"Supplement 5","key":"10.1016\/j.ejca.2021.02.007_bib8","article-title":"Clinical practice guidelines Prevention and screening in BRCA mutation carriers and other breast\/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention clinical practice guidelines","volume":"27","author":"Paluch-Shimon","year":"2016","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2021.02.007_bib9","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo- oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2021.02.007_bib10","series-title":"Two decades after BRCA: setting care and prevention","first-page":"1466","author":"Couch","year":"2014"},{"key":"10.1016\/j.ejca.2021.02.007_bib11","first-page":"1","article-title":"Breast cancer risk after salpingo-oophorectomy in healthy BRCA1\/2 mutation Carriers: revisiting the evidence for risk reduction","volume":"107","author":"Seynaeve","year":"2015","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2021.02.007_bib12","series-title":"Genetic\/familial high-risk Assessment\u00a0: breast and ovarian","author":"National Comprehensive Cancer Network Guidelines","year":"2019"},{"issue":"4","key":"10.1016\/j.ejca.2021.02.007_bib13","first-page":"483","article-title":"Long-term health consequences of premature or early menopause and considerations for management","volume":"18","author":"Faubion","year":"2016"},{"issue":"22","key":"10.1016\/j.ejca.2021.02.007_bib14","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.2005.05.1896","article-title":"The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy","volume":"24","author":"Madalinska","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2021.02.007_bib15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10549-016-3685-3","article-title":"Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case\u2013control study","volume":"155","author":"Kotsopoulos","year":"2016","journal-title":"Breast Canc Res Treat"},{"issue":"22","key":"10.1016\/j.ejca.2021.02.007_bib16","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1001\/jama.2017.16952","article-title":"Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: evidence report and systematic review for the US preventive services task force","volume":"318","author":"Gartlehner","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ejca.2021.02.007_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10549-007-9523-x","article-title":"Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study","volume":"107","author":"Fournier","year":"2008","journal-title":"Breast Canc Res Treat"},{"issue":"31","key":"10.1016\/j.ejca.2021.02.007_bib18","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.1200\/JCO.2004.00.8151","article-title":"Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group","volume":"23","author":"Rebbeck","year":"2005","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2021.02.007_bib19","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/jnci\/djn313","article-title":"Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers","volume":"100","author":"Eisen","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2021.02.007_bib20","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.1501","article-title":"Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer?No Title","volume":"29","author":"Domchek","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2021.02.007_bib21","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jamaoncol.2018.0211","article-title":"Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers","volume":"4","author":"Kotsopoulos","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2021.02.007_bib22","first-page":"1","article-title":"The effect of hormone therapy on quality of life and breast cancer risk after risk-reducing salpingo-oophorectomy: a systematic review","volume":"17","author":"Siyam","year":"2017","journal-title":"BMC Wom Health"},{"issue":"1","key":"10.1016\/j.ejca.2021.02.007_bib23","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2018.12.014","article-title":"Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits","volume":"153","author":"Gordhandas","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"September","key":"10.1016\/j.ejca.2021.02.007_bib24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.critrevonc.2018.09.018","article-title":"Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a meta-analysis","volume":"132","author":"Marchetti","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ejca.2021.02.007_bib25","series-title":"Society at a glance 2014 highlights: Israel, OECD","first-page":"1","author":"OECD","year":"2014"},{"issue":"6","key":"10.1016\/j.ejca.2021.02.007_bib26","doi-asserted-by":"crossref","first-page":"9144","DOI":"10.18632\/oncotarget.13423","article-title":"The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation","volume":"8","author":"Toss","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.ejca.2021.02.007_bib27","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju091","article-title":"Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis","volume":"106","author":"Friebel","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.ejca.2021.02.007_bib28","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/jnci\/djj132","article-title":"Pregnancies, breast-feeding, and breast cancer risk in the international BRCA1\/2 carrier cohort study (IBCCS)","volume":"98","author":"Andrieu","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.ejca.2021.02.007_bib29","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jamaoncol.2020.2059","article-title":"Presymptomatic awareness of germline pathogenic BRCA variants and associated outcomes in women with breast cancer","volume":"6","author":"Hadar","year":"2020","journal-title":"JAMA Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921000897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921000897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:30:12Z","timestamp":1760733012000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921000897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":29,"alternative-id":["S0959804921000897"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.02.007","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}